Timed Instillation of Medicated Eyedrops in Glaucoma Patients

I0 sites0 target enrollmentTBD

Overview

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

3 years ago

Study Type

Interventional

Sponsor

•Patients age \>18 years with a diagnosis of primary open angle glaucoma, including pigmentary glaucoma, and pseudoexfoliation, managed on multiple topical glaucoma medications with concurrent administration of medication at a minimum of one time point in the day. Concurrently prescribed eye drops include any of the following classes with twice daily dosing schedules: topical alpha agonists, topical beta blockers, and topical carbonic anhydrase inhibitors. The study includes 3 groups
•1\.Timolol and Brimonidine
•2\.Timolol and Dorzolamide
•3\.Brimonidine and Dorzolamide

•Patients with congenital, angle closure, juvenile open angle glaucoma, or secondary forms of glaucoma, aside from pseudoexfoliation and pigment dispersion syndrome) will be excluded from this study. Previous surgery for glaucoma (either subconjunctival or angle\-based), previous cyclodestructive procedures, previous iridotomy, previous trabeculoplasty, or other incisional eye surgery for the last 6 months will be excluded. Individuals with an abnormal slit lamp examination (except for cataract/IOL) will be excluded.
•Individuals who have used one of the following eyedrop medications within the last 28 days of the study, or during the study: Prostaglandin analogues,Rho\-kinase inhibitors, Parasympathomimetics (pilocarpine, echothiophate) will also be ineligible for participation. Patients on concomitant oral carbonic anhydrase inhibitors are also ineligible for participation.

Not specified